If you are interested in learning more or applying for our open July 2026 position, please reach out โ we would love to hear from you!
Contact Us: Dr. Heta Javeri, MD (program director)- [email protected] Lizette Gonzalez (program coordinator)- [email protected]
๐ Now Recruiting: ID Fellows โ July 2026 Start
A career in Infectious Diseases is incredibly rewarding, offering diverse clinical practice, meaningful patient impact, and excellent work life balance. We currently have open positions in our program and invite you to apply!
Next up: DOTS trial studying dalbavancin vs SOC for SAB (33% MRSA). Primary outcome DOOR at day 70, designed as superiority analysis. Good mix of infection sources including endovascular.
@ESCMID#ESCMIDGlobal2024
We are thrilled to welcome our 2024 Infectious Diseases fellows! We still have one spot available. If interested please email [email protected] for more information.
Get ready for another excellent in-person bug ๐ฆ club with @UTHSA_AETC this evening at La Quinta ๐๐ผ๐ฉ๐ผโโ๏ธ๐ง๐ฝโโ๏ธ#idtwitter#texasid
Excited for our first in-person City Wide Bug Club in a long time @UTHSA_AETC ๐
Sign up ๐๐ผ See you all at La Quinta this evening!
https://t.co/oSFEmyN5hZ
Check out the poster on "Flea-borne typhus causing HLH" at #astmh2022 at noon today, by fellow @dr_sketchartist, faculty mentor @GregoryAnstead3 ๐ฆ Log in to the chat function and post your qs virtually #IDtwitter!
Great presentation by our ID pharmacists, Amber Welborn;Emily Kirkpatrick, w/ data on involvement of pharmacists in HIV care-including ๐ฝ hospitalizations; ๐ผ CD4 upto 60 cells/mm3; ๐ผ adherence.
To catch case presentation by our ID fellow, tune in now!
@UTHSA_AETC@UHPharmRes
Catch tomorrow's @uthsaim grand rounds presentation by our very own @DrBarbaraTaylor titled "Can we end the HIV epidemic now? New tools and lessons learned from COVID-19 vaccine development and roll out"! Excited to hear this talk at 8:00 CST on 10/26๐ก๐ฉบ๐ฆ
Currently, MALDI-TOF/ 16 s-RNA sequencing helps identify this organism.
As this is skin flora, interpretation of pathogenicity/ role in disease process is carefully interpreted.
Our patient is receiving Dalbavancin for vertebral osteo treatment targeting this organism.
#IDtwitter 45 yo w/ L4-5 discitis/OM now, h/o L5-S1 OM (destructive changes at this level๐๐ผ) Rx 2015 w/ vanc/cefepime x6wk empirically (Pt not open to biopsy then).Unrelenting LBP continued->multiple steroid injections->Corynebacterium tuberculostearicum on biopsy this occasion!
"... isolation of C. tuberculostearicum from human clinical samples is underreported since this species is not included in the API Coryne database and is therefore systematically misidentified as other lipophilic corynebacteria such as C. macginleyi or C. jeikeium."